MorphoSys Granted Fifth US Patent for its Core Antibody Technology - - BioPharm International


MorphoSys Granted Fifth US Patent for its Core Antibody Technology

BioPharm Bulletin

The US Patent & Trademark Office has issued the fifth US patent to MorphoSys AG (Munich, Germany) stemming from MorphoSys’s base HuCAL (human combinatorial antibody library) patent family, providing extended protection to MorphoSys’s core technology. The new patent (US 7,264,963) captures HuCAL’s modular design at the DNA level, providing solid product claim protection in the US.

MorphoSys’s HuCAL libraries comprise highly diverse, fully human synthetic antibodies that are highly engineerable through their modular CDR design. In its most advanced marketed version, HuCAL provides access to fully human antibodies as research tools, diagnostics, and therapeutics. The US Patent Office issued the first HuCAL patent in 2001, and patents have also been granted in Australia and at the European Patent Office. To date, MorphoSys has been granted more than 15 patents and more than 40 applications are pending worldwide.

MorphoSys release

blog comments powered by Disqus



UPS' Pain in the Supply Chain Results
September 23, 2014
Merck KGaA Announces Acquisition of Sigma-Aldrich for $17 Billion
September 22, 2014
Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here